Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Emec who wrote (1243)	1/4/1999 12:30:00 AM
From: jake burns	Respond to of 1510

I personally think IMNR has great science which is understood fully by their corporate partners, but not by the Street. Unfortunately, that's what is important for a corporation's stock price. And until earnings are realized (after drugs are approved and marketed), Wall Street is apt to sit on the sidelines. However, because Wall Street underappreciates IMNR, it's possible that a company like Agouron (whose currency is extremely valuable now that AGPH is 60 rather than 30 dollars a share) will step in at this time and make an acquisition. They, as well as SGP and the other big pharmaceutical companies, do value IMNR's science and can purchase this company for a song in a stock swap deal....Heck, based on today's stock prices, a 1 for 2 stock swap would equate to about a 580 million dollar valuation on IMNR, or a 51 dollar share price on a combined agph/imnr entity and a 25.50/sh. price for IMNR shareholders. In my view it's a win/win situation for agph and imnr shareholders....and a fairly inexpensive way for agph to acquire imnr's science. Just my 6 cents.